Articles

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Alexandra Hospital, Athens, Greece
Hematology & Oncology, Department of Medicine, University Hospital Tübingen, Germany
Vancouver General Hospital, Vancouver, BC, Canada
Department of Hematology, University Hospital Leuven, Belgium
Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Bénite, France
University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany
Hematology, University Hospital Hôtel-Dieu, Nantes, France
Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France
Institut Catala d’Oncologia, HGTiP, Barcelona, Spain
Hopital Saint Antoine, Paris, France
Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy
GUZ Moscow City Clinical Hospital S.P. Botkin, Russia
Hospital Universitario La Princesa, Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Princess Margaret Hospital, Toronto, ON, Canada
Alfred Hospital-Monash University, Melbourne, Australia
University of Würzburg, Germany
University of Calgary, AB, Canada
University Hospital Zurich, Switzerland
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Clinica Universidad de Navarra, CIMA, Pamplona, Spain
Vol. 100 No. 10 (2015): October, 2015 https://doi.org/10.3324/haematol.2014.117077